Multidimensional Impact of Telemonitoring in Heart Failure (IMPACT-HF)

Launched by HOSPITAL UNIVERSITARIO 12 DE OCTUBRE · Dec 7, 2022

Keywords

ClinConnect Summary

The IMPACT-HF clinical trial is studying how telemonitoring—using technology to keep track of patients' health from home—affects the care and costs for people with heart failure. The researchers want to find out if this approach can help reduce the number of hospital visits and overall healthcare costs for patients at high risk of heart failure. Participants in the study will be randomly assigned to either receive standard care or telemonitoring, which includes daily checks of their blood pressure, heart rate, and weight, along with virtual consultations with a specialized heart failure team.

To be eligible for the trial, participants should have been diagnosed with heart failure for at least three months and have had recent issues that required hospital care. They should also be receiving treatment with specific heart medications. Those who have serious health complications or cannot use technology may not qualify. If you join, you can expect to take part in regular health monitoring and discussions with healthcare professionals, which could help improve your heart health while also providing valuable information for the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of HF according to the 2021 guidelines of the European Society of Cardiology criteria for ≥3 months.
• • Admitted for decompensation of chronic HF.
• • Admitted for HF decompensation ≥30 days and ≤6 months.
• • HF decompensation in ≥30 days and ≤6 months but discharged directly from the emergency department or managed on an outpatient basis, but requiring intravenous diuretic administration in an ambulatory basis, or \>50% increase in loop diuretic dose.
• • With previous optimized prognostic medical treatment.
• • Under treatment with loop diuretic drugs.
• • New York Heart Association functional class II, III or IV.
• Exclusion Criteria:
• • Inclusion in other intervention studies.
• • Hemodynamic instability.
• • Acute myocardial infarction, acute pulmonary thromboembolism or stroke in the previous 40 days.
• • Uncontrolled arrhythmias
• • On waiting list for transplantation (any organ) or other cardiac surgery.
• • Advanced mechanical circulatory support.
• • Chronic renal disease on hemodialysis.
• • Life expectancy less than 1 year.
• • Moderate-severe cognitive impairment.
• • Manifest inability to use a technological system.
• • Institutionalized.
• • Limiting psychiatric pathology.